Clinical Characteristics
Cognitive Impairment, cognitive impairment, dementia, Dementia, Alzheimer’s Disease
ALZHEIMER DISEASE
Abbreviations: Aβ, amyloid β; AD, Alzheimer disease; ADAS-Cog 14, 14-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADCS-ADL-MCI, Alzheimer’s Disease Cooperative Study-Activities of Daily Living for Mild Cognitive Impairment; CDR-SB, Clinical Dementia Rating Sum of Box; MMSE, Mini-Mental State Examination; WMS-R, Wechsler Memory Scale-Revised.SI conversion factor: To convert blood albumin level to grams per liter, multiply by 10.Calculated as weight in kilograms divided by height in meters squared.Scores range from 0 to 30, with lower scores indicating greater cognitive impairment.Scores range from 0 to 18, with higher scores indicating severe dementia.Scores range from 0 to 90, with higher scores indicating worse cognitive function.Scores range from 0 to 25, with lower scores indicating worse cognitive function.Scores range from 0 to 53, with lower scores indicating severe activities of daily living impairment.Among patients who received the treatment protocol until the 96-week visit without early termination, 48 (61.5%) were in the cilostazol group and 55 (67.9%) were in the placebo group. Among 103 patients who completed the 96-week treatment protocol, 61 (59.2%) were female and 42 (40.8%) were male. The mean (SD) age was 75.6 (5.0) years, the mean (SD) baseline MMSE score was 25.9 (1.8), and the mean (SD) CDR-SB score was 2.5 (0.9). Among 56 patients with early termination, 32 (57.1%) were female and 24 (42.9%) were male. The mean (SD) age was 75.6 (5.6) years, the mean (SD) baseline MMSE score was 25.0 (1.9), and the mean (SD) CDR-SB score was 2.8 (1.0). After early termination, 8 patients in the cilostazol group and 5 in the placebo group were followed up until the 96-week visit. Of the 159 patients who had initiated the treatment protocol in this trial, 116 (73.0%) attended their final 96-week visit. The drug-adherence rates are presented in eTable 2 in 